Shelf life (days): 1460.0
Formulation: A solid
Formal Name: N-[(1S)-1-[[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxy-d3-carbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-carbamic acid, methyl-d3 ester
Purity: ≥99% deuterated forms (d1-d6)
Formula Markup: C49H48D6F2N8O6
Formula Weight: 895.1
CAS Number: 2050041-12-6
Notes: Ledipasvir-d6 is intended for use as an internal standard for the quantification of ledipasvir (Item No. 18519) by GC- or LC-MS. Ledipasvir is an inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A).{53973,53974} It inhibits viral replication in genotype 1a and 1b HCV replicon cells (EC50s = 0.031 and 0.004 nM, respectively). It also inhibits viral replication in genotype 2a, 2b, 3a, 4a, 4d, 5a, 6a, and 6e HCV replicon cells (EC50s = 0.11-530 nM).{53974} Lepidasvir acts synergistically with IFN-α, ribavirin (Item No. 16757), or GS-9669 and additively with GS-9451, simeprevir (Item No. 22144), daclatasvir (Item No. 23730), or PSI-7977 (sofosbuvir; Item No. 15402) to inhibit viral replication in genotype 1a HCV replicon cells. Formulations containing ledipasvir have been used in combination therapy for the treatment of chronic HCV infection.
Deutsch
English
